Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe

被引：0

作者：

Hwang, T. ^{[1
]}

Vokinger, K. ^{[2
]}

Tibau, A. ^{[3
]}

Gyawali, B. ^{[4
]}

Naci, H. ^{[5
]}

Franklin, J. M. ^{[1
]}

Beall, R. ^{[1
]}

Kesselheim, A. ^{[1
]}

机构：

[1] Harvard Med Sch, Program Regulat Therapeut & Law, Boston, MA 02115 USA

[2] Univ Zurich Hosp, Med, Zurich, Switzerland

[3] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain

[4] Brigham & Womens Hosp, Dept Med Oncol, 75 Francis St, Boston, MA 02115 USA

[5] London Sch Econ, Hlth Policy, London, England

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1555O_PR

引用

页码：752 / 752

页数：1

共 50 条

[1] RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON OVARIAN CANCER
Gittings, K.
Gittings, K.
Campbell, D.
Riggs, K.
Meyer, K. L.
[J]. VALUE IN HEALTH, 2019, 22 : S97 - S98
[2] DOES USING CLINICAL TRIALS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) ECONOMIC MODELLING IMPACT REIMBURSEMENT DECISIONS?
Inumerable, R. V. F.
Rubinstein, J.
[J]. VALUE IN HEALTH, 2020, 23 : S139 - S139
[3] Analysis of Health Technology Assessment (HTA) Procedures and Outcomes for Orphan Drugs
Warttig, S.
D'Souza, V
[J]. VALUE IN HEALTH, 2022, 25 (12) : S334 - S335
[4] Clinical benefit and prices of cancer drugs in the US and Europe
Vokinger, K. N.
Hwang, T.
Tibau, A.
Rosemann, T. J.
Kesselheim, A. S.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[5] Does health technology assessment benefit health services and politics? The experiences of an established HTA institution: The Danish centre for evaluation and HTA
Sigmund H.
Kristensen F.B.
[J]. The European Journal of Health Economics, 2002, 3 (1) : 54 - 58
[6] RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON PROSTATE CANCER: RESULTS, RATIONALE, AND TRENDS
Campbell, D.
Gittings, K.
Kanaskar, A.
Riggs, K.
Meyer, K. L.
[J]. VALUE IN HEALTH, 2019, 22 : S505 - S505
[7] HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe
Bento, G.
Dumoulin, O.
Reinert, M.
Gulotta, G.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S336 - S336
[8] WIDER CONSULTATION IN HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS: BETTER UNDERSTANDING OR A LOBBYING OPPORTUNITY?
Bending, M. W.
Hutton, J.
McGrath, C.
[J]. VALUE IN HEALTH, 2011, 14 (03) : A22 - A22
[9] DIVERGENT HTA DECISIONS IN EUROPE FOR ONCOLOGY DRUGS GRANTED BREAKTHROUGH DESIGNATION
Borissov, B.
[J]. VALUE IN HEALTH, 2019, 22 : S100 - S100
[10] IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN THE UK
Cocklin, S.
Papanicolaou, S.
Jones, C.
[J]. VALUE IN HEALTH, 2018, 21 : S117 - S117

← 1 2 3 4 5 →